Evidence map›Paper›PMID 30498189›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer.

Liang Shi, Yiming Li, Tingting Yu, Zeng Wang, Chenxi Zhou, Wenxiu Xing, Gaoqi Xu, BingLei Tong, Yingchao Zheng, Jie Zhou and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Liang ShiZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
Yiming LiZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Drug Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China (mainland).
Tingting YuXihu District Hangzhou SanDu Town Community Health Service Center, Hangzhou, Zhejiang, China (mainland).
Zeng WangZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
Chenxi ZhouZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
Wenxiu XingZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
Gaoqi XuZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
BingLei TongCell-Land Biological Technology, Hangzhou, Zhejiang, China (mainland).
Yingchao ZhengPharmacy College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China (mainland).
Jie ZhouZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Drug Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China (mainland).
Ping HuangZhejiang Cancer Hospital, Hangzhou, Zhejiang, China (mainland).
Zhejiang Cancer Hospital · CNZhejiang University · CNCell Technology (China) · CNCommunity Health Center · USZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood. MATERIAL AND METHODS Pre-chemotherapy platelet activation index and CA125 were retrospectively evaluated in 169 advanced and metastatic NSCLC patients. All variables were screened by chi-square test and then evaluated by log-rank test. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed by using Cox proportional hazards model. RESULTS The overall rate of GP resistance for NSCLC patients was 72.19%. Mean platelet volume (MPV) and plateletcrit (PCT) are negative predictors of GP resistance adenocarcinoma [Odds ratio (OR): 5.81, 95% confidence interval (CI): 1.082-31.195, P=0.004] and squamous cell carcinoma (PCT: R: 3.517, 95% CI: 1.087-11.387, P=0.036), respectively. But both were an independent factor associated with overall survival (OS). Moreover, only CA125 was a dependent factor associated with OS for squamous cell carcinoma [OS: hazard ratio (HR): 1.741, 95% CI: 1.002-3.024, P=0.049; GP resistance: OR: 4.862, 95% CI: 1.437-16.448, P=0.011]. CONCLUSIONS Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGemcitabineHumansLung NeoplasmsMaleMiddle AgedPlatelet ActivationCisplatinDeoxycytidineGemcitabine

Identifiers

PMID30498189
PMCPMC6284361
OpenAlexW2902676634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.